<?xml version="1.0" ?>
<text author="Jose-Manuel delMoral-Sanchez, Isabel Gonzalez-Alvarez, Marta Gonzalez-Alvarez, Andres Navarro, Marival Bermejo" dateCollected="2019-11-03" id="autogum_academic_doc456" shortTile="classification-essential" sourceURL="https://www.mdpi.com/1999-4923/11/11/567/htm" speakerCount="0" speakerList="none" title="Classification of WHO Essential Oral Medicines for Children Applying a Provisional Pediatric Biopharmaceutics Classification System" type="academic">
<head>
<s>
1
.
</s>
<s>
Introduction
</s>
</head>
<p>
<s>
The
objective
of
this
paper
was
using
the
Essential
Medicines
List
for
children
by
the
World
Health
Organization
(
WHO
)
to
create
a
provisional
pediatric
biopharmaceutics
classification
system
(
pBCS
)
for
oral
drugs
and
to
compare
our
results
with
the
BCS
for
adults
(
aBCS
)
.
</s>
</p>
<p>
<s>
Since
2007
,
the
WHO
has
provided
the
WHO
Model
List
of
Essential
Medicines
for
Children
;
a
core
drug
list
for
a
basic
health-care
system
.
</s>
<s>
This
resource
list
considers
the
safest
,
efficacious
and
cost-effective
drugs
for
priority
pathologies
in
pediatrics
up
to
12
years
old
.
</s>
<s>
All
immediate
release
oral
drugs
from
the
sixth
edition
of
this
list
were
selected
for
this
work
.
</s>
</p>
<p>
<s>
The
need
for
and
importance
of
developing
appropriate
,
safe
and
effective
medicines
for
pediatrics
have
now
been
recognized
.
</s>
<s>
Pediatrics
have
long
been
considered
as
a
therapeutically
disregarded
group
.
</s>
<s>
This
fact
lies
in
the
therapeutic
gap
that
originates
from
formulation
development
(
mainly
focused
on
adults
)
,
low
availability
of
commercial
pediatric
drugs
for
pediatric
use
and
physiological
and
anatomical
differences
relative
to
the
adult
population
.
</s>
</p>
<p>
<s>
In
younger
pediatrics
,
neonates
and
infants
,
the
therapeutic-risk
benefits
associated
with
drug
treatment
may
be
different
from
those
in
adults
.
</s>
<s>
Developmental
physiological
differences
(
as
the
composition
of
gastrointestinal
fluids
and
the
presence
or
activity
of
intestinal
drug
metabolizing
enzymes
and
efflux
transporters
)
can
markedly
alter
the
bioavailability
of
drugs
.
</s>
<s>
Age-related
changes
in
the
characteristics
of
luminal
fluids
such
as
pH
may
lead
to
changes
in
drug
solubility
and
,
therefore
,
in
absorption
since
only
the
dissolved
drug
would
be
available
for
absorption
.
</s>
<s>
Since
fluctuations
in
pH
may
influence
ionizable
drugs
and
the
relative
amount
of
unionized
available
drug
,
there
could
be
changes
in
absorption
during
maturation
.
</s>
<s>
The
gastric
pH
of
the
newborn
is
approximately
neutral
,
and
within
the
first
48
h
of
life
,
the
gastrointestinal
pH
decreases
to
adult
values
and
then
for
the
first
month
increases
back
to
values
close
to
neutrality
.
</s>
<s>
After
the
first
month
,
gastric
pH
decreases
progressively
to
reach
similar
values
as
in
adults
by
two
years
of
age
.
</s>
</p>
<p>
<s>
On
the
other
hand
,
another
determinant
of
bioavailability
is
ontogenic
changes
in
the
expression
of
drug
metabolizing
enzymes
and
transporters
,
which
would
mark
the
first
pass
effect
and
consequently
would
change
the
oral
absorbed
fraction
.
</s>
<s>
For
example
,
the
CYP3A4
isoenzyme
increases
expression
and
activity
with
age
.
</s>
<s>
CYP3A4
is
practically
undetectable
in
neonates
,
and
its
expression
increases
with
age
,
reaching
a
maximum
level
at
two
years
of
age
.
</s>
<s>
Likewise
,
in
these
age
groups
,
there
is
immature
intestinal
activity
of
alkaline
phosphatase
,
glucuronidation
enzymes
and
carboxylesterase-2
.
</s>
<s>
Conversely
,
there
are
no
differences
in
p-glycoprotein
expression
,
the
most
studied
intestinal
efflux
transporter
from
the
earliest
stages
of
life
to
adults
.
</s>
</p>
<p>
<s>
Many
drugs
are
formulated
as
pharmaceutical
forms
that
are
often
not
appropriate
for
pediatrics
,
such
as
tablets
or
capsules
.
</s>
<s>
Children
need
different
oral
dosage
formulations
from
adults
mainly
due
to
their
developmental
capabilities
in
swallowing
ability
,
palatability
and
dosage
requirements
.
</s>
<s>
Especially
in
pediatrics
,
palatability
is
closely
related
to
acceptance
and
adherence
.
</s>
<s>
Consequently
,
bitterness
,
trigeminal
irritation
and
perceptible
malodors
must
be
minimized
.
</s>
</p>
<p>
<s>
The
increasing
need
for
age-related
medicines
in
pediatrics
could
be
met
by
extemporaneous
formulations
.
</s>
<s>
The
compounding
of
an
extemporaneous
formula
is
not
allowed
if
an
authorized
commercial
pharmaceutical
product
(
adequate
for
a
particular
age
group
)
exists
,
but
the
reality
in
the
clinical
setting
is
that
for
some
age
groups
,
that
is
not
the
case
,
while
extemporaneous
formulation
is
still
used
as
the
only
alternative
to
the
therapeutic
need
.
</s>
<s>
Although
solid
products
have
higher
stability
than
liquid
formulations
,
this
practice
can
solve
the
problem
of
swallowing
capability
and
dose
adjustments
,
but
these
manufactured
preparations
can
be
a
risk
to
safety
,
efficacy
and
quality
,
because
there
is
little
or
no
information
for
compatibility
between
the
original
medicine
and
additional
excipients
or
their
effect
in
children
.
</s>
<s>
The
excipients
used
in
formulations
designed
for
children
should
be
appropriate
for
each
age
group
because
,
as
is
known
,
these
are
not
inert
substances
and
cannot
be
supposed
to
have
the
same
effects
in
pediatrics
as
in
adults
.
</s>
<s>
The
most
common
example
is
early
stage
children
who
are
not
able
to
metabolize
or
eliminate
them
as
adults
.
</s>
<s>
The
ideal
situation
in
the
development
of
pediatric
formulations
is
the
minimal
use
of
added
excipients
,
both
in
number
and
quantity
.
</s>
</p>
</text>
